– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

Price trend, volume and key moving averages
Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 12, 2026 | -$1.90-15.9% vs -$1.64 | — vs $14M |
Q3 2026 Aug 12, 2026 | -$2.33-6.4% vs -$2.19 | $10M-17.7% vs $12M |
Q2 2026 May 14, 2026 | -$2.94-26.7% vs -$2.32 | $15M+63.3% vs $9M |
Q2 2026 Mar 23, 2026 | -$5.29+35.2% vs -$8.16 | $12M+25.8% vs $9M |
– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.
Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Benchmark STRO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Sutro Biopharma, Inc. (STRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.50 | $82.26M | -0.91 | 65.18% | -344.22% | — | — | |
| $15.76 | $1.98B | -4.51 | -4.26% | -445% | -90.04% | — | |
| $5.10 | $9.8M | -0.39 | 0.07% | -1027.93% | -154.11% | — | |
| $34.42 | $1.18B | -6.64 | -43.89% | -339.67% | -29.31% | — | |
| $29.68 | $1.77B | -4.75 | 48.03% | -264.76% | -34.63% | — | |
| $1.97 | $125.22M | -2.44 | 0.78% | -45.37% | -142.22% | — |
Sutro Biopharma, Inc. (STRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Sutro Biopharma, Inc. (STRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 8, 2026·SEC
May 14, 2026·SEC
Get notified when STRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Sutro Biopharma, Inc. (STRO) stock FAQ — growth, dividends, profitability & financials explained
Sutro Biopharma, Inc. (STRO) reported $45.1M in revenue over the trailing twelve months. Revenue was $102.5M in fiscal year 2025. That is 72% more than the $59.7M of fiscal year 2016.
Sutro Biopharma, Inc. (STRO) revenue fell by 57.3% over the trailing twelve months, compared with the twelve months before.
No. Sutro Biopharma, Inc. (STRO) reported a net loss of $155.3M over the trailing twelve months.
Sutro Biopharma, Inc. (STRO) had negative free cash flow of $129.8M over the trailing twelve months.